The 2025 South Central AUA annual meeting included a session on urothelial cancer, featuring a presentation from Dr. Patrick Burnam discussing long-term outcomes of adjuvant UGN-101 in a real-world ...

The immune checkpoint inhibitor combination regimen has become the initial standard of care for metastatic RCC, given its ...

Dr. Palacios concluded his presentation discussing the role of an intraoperative steep Trendelenburg break during robot-assisted laparoscopic radical prostatectomies with the following take-home ...

Detalimogene voraplasmid is a novel, investigational, non-integrating, non-viral genetic medicine-based immunotherapy carrying a plasmid that simultaneously expresses IL-12 and regulators of RIG-I.

The 2025 South Central AUA annual meeting included a session on bladder cancer, featuring a trials in progress presentation from Dr. Yair Lotan discussing a streamlined, patient-centric design of the ...

A total of 4,483 FDG PET/CTs were performed during the study period, of which 112 (2.5%) FDG PET/CTs incidentally revealed a FDG avid prostate lesion. There were 105 unique patients with incidental ...

The 2025 South Central AUA annual meeting included a session on kidney cancer, featuring a presentation from Dr. Horst Emanuel Lagos Beitz discussing the identification of predictive risk factors to ...

The 2025 South Central AUA annual meeting included a session on kidney cancer, featuring a presentation from Dr. Vedant Agrawal discussing patient-reported barriers, social determinants, and racial ...

The 2025 South Central AUA annual meeting included a session on bladder cancer, featuring a presentation from Dr. Yair Lotan ...

(UroToday.com) The 2025 South Central AUA annual meeting included a session on bladder cancer, featuring a presentation from Dr. Janet Kukreja discussing a pilot study of a web-based urinary diversion ...

The baseline characteristics of the two cohorts are as follows: ...

This was a descriptive, observational, and retrospective study of patients who underwent radical prostatectomy and PSMA PET/CT for staging between October 2019 and May 2024. The objective of the study ...